Tefludazine

TargetMol
Product Code: TAR-T67811
Supplier: TargetMol
CodeSizePrice
TAR-T67811-1mg1mg£263.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67811-5mg5mg£544.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67811-10mg10mg£748.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67811-25mg25mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67811-50mg50mg£1,460.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67811-100mg100mg£1,942.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67811-500mg500mg£3,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Tefludazine, a novel neuroleptic with a benzindone structure, is a compound with good oral activity and antagonistic effects on dopamine and 5-hydroxytryptamine receptors. Tefludazine has shown potent dopamine (DA) antagonistic activity in in vitro and in vivo test models in mice, rats and dogs. Tefludazine is a therapeutic agent used to treat psychiatric disorders.
CAS:
80680-06-4
Molecular Weight:
408.43
Purity:
0.9954
SMILES:
FC(F)(C1=CC=C([C@H](C2=CC=C(C=C2)F)C[C@H]3N4CCN(CC4)CCO)C3=C1)F

References

Liljefors T, et al. Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. J Med Chem. 1988;31(2):306-312. Skarsfeldt T. Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in rats. Life Sci. 1988;42(10):1037-1044.